We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Risperdal Consta and Health Care Utilization in Patients With Schizophrenia

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 12, 2006
Last Update Posted: September 25, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Janssen, L.P. - Investigator Initiated Studies Program
Information provided by:
Emory University
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.

Condition Intervention Phase
Schizophrenia Schizoaffective Disorder Drug: Risperdal Consta Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: The Effects of Risperdal Consta on Health Care Utilization Costs in Chronically Ill Schizophrenic Patients

Resource links provided by NLM:

Further study details as provided by Emory University:

Study Start Date: December 2005
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Primary diagnosis of schizophrenia or schizoaffective disorder
  • 4 or more admissions to psychiatric hospital in past year, OR minimum of 2 hospital admissions and at least 2 incarcerations in the previous year
  • Medicaid recipient
  • Patients requiring concomitant non-antipsychotic psychotropic medication (mood stabilizing, antidepressants, anxiolytics)

Exclusion Criteria:

  • Past or current psychiatric disorder, other than schizophrenia or schizoaffective disorder
  • Drug or alcohol dependence
  • Serious, unstable medical illness or any acute medical condition
  • Pregnant or lactating females
  • Prior Risperdal Consta treatment
  • Non-English speaking
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00313391

United States, Georgia
Grady Hospital
Atlanta, Georgia, United States
Sponsors and Collaborators
Emory University
Janssen, L.P. - Investigator Initiated Studies Program
Principal Investigator: Dragana Bugarski-Kirola, MD Emory University
  More Information

Responsible Party: Dragan Bugarski-Kirola, MD, Emory University
ClinicalTrials.gov Identifier: NCT00313391     History of Changes
Other Study ID Numbers: 731-2005
First Submitted: April 10, 2006
First Posted: April 12, 2006
Last Update Posted: September 25, 2014
Last Verified: September 2014

Additional relevant MeSH terms:
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents